Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Harvard Bioscience, Inc. (HBIO)

8.90 +0.10 (+1.14%)
At close: October 30 at 4:00:01 PM EDT
Chart Range Bar
Loading chart for HBIO
Chart does not reflect overnight price.
  • Previous Close 8.80
  • Open 8.80
  • Bid 6.29 x 200
  • Ask 10.88 x 200
  • Day's Range 8.80 - 8.92
  • 52 Week Range 4.00 - 9.00
  • Volume 23,170
  • Avg. Volume 19,279
  • Market Cap (intraday) 40.516M
  • Beta (5Y Monthly) 1.51
  • PE Ratio (TTM) --
  • EPS (TTM) -2.31
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 7.50

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

www.harvardbioscience.com

316

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HBIO
32.84%
S&P 500 (^GSPC)
10.73%

1-Year Return

HBIO
41.27%
S&P 500 (^GSPC)
11.11%

3-Year Return

HBIO
79.16%
S&P 500 (^GSPC)
81.91%

5-Year Return

HBIO
88.18%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 22.73M
Earnings -2.91M
Profit Margin -12.80%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5M
10M
15M
20M
-16.0%
-14.0%
-12.0%
-10.0%
-8.0%
-6.0%

Analyst Insights

View More

Analyst Price Targets

7.50 Low
7.50 Average
8.90 Current
7.50

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/12/2026
Analyst Benchmark
Rating Action Maintains
Rating Speculative Buy
Price Action Raises
Price Target 6 -> 7.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.86%

  • Return on Assets (ttm)

    1.58%

  • Return on Equity (ttm)

    -89.95%

  • Revenue (ttm)

    87.81M

  • Net Income Avi to Common (ttm)

    -10.41M

  • Diluted EPS (ttm)

    -2.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.5M

  • Total Debt/Equity (mrq)

    595.93%

  • Levered Free Cash Flow (ttm)

    5.3M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: